Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will …

chronic lymphocytic leukemia
lymphoid leukemia
lymphoma
richter's syndrome
tyrosine
  • 7 views
  • 15 May, 2022
  • 8 locations
AZD9833 China PK Study (AZD9833)

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer.

  • 0 views
  • 29 May, 2022
  • 1 location
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

fludarabine
etoposide
cytarabine
imatinib
ifosfamide
  • 0 views
  • 24 Jan, 2021
  • 1 location
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

  • 88 views
  • 16 Jun, 2022
  • 14 locations
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)

The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease.

letrozole
measurable disease
gonadotropin releasing hormone
exemestane
anastrozole
  • 0 views
  • 30 Jan, 2022
  • 1 location
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D). Primary Objective Dose Expansion: To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract Cancer …

primary cancer
solid tumor
sunitinib
everolimus
sarcoma
  • 83 views
  • 13 May, 2022
  • 12 locations
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024)

STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)]. STAGE 2: To demonstrate the efficacy and safety of enobosarm 9 mg QD in combination with abemaciclib …

  • 0 views
  • 04 Jun, 2022
  • 3 locations
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors (COMBOREIN)

The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted …

ATM
renal neoplasm
carcinoma
clear cell renal cell carcinoma
temsirolimus
  • 4 views
  • 04 Mar, 2022
  • 1 location
ANGiographic Evaluation of Left Main Coronary Artery INtErvention (ANGELINE)

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

everolimus
stroke
percutaneous coronary intervention
angiography
infarct
  • 0 views
  • 07 Jun, 2022
  • 30 locations
Selective Treatment According to Molecular Subtype of Prostate Cancer (STAMP)

This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal …

serum testosterone
testosterone
  • 1 views
  • 14 Feb, 2022
  • 1 location